In contrast to previous results that have shown worse prognoses for stage II and III CDX2-negative colorectal cancers compared with CDX2-positive cancers, the current analysis did not disclose significant differences in survival outcomes [11,40]. This evidence concerns the gene CDX2 and colorectal cancer.